Selinexor, anti-PD-1 antibody plus Golidocitinib
1 treatment and condition followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Selinexor, anti-PD-1 antibody plus Golidocitinib for lymphoma, extranodal nk-t-cell | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |